€15m · Series A · Healthtech · Montpellier, France
Montpellier-based Lupin Dental has closed a €15 million Series A to develop and expand its supervised dental-robotics platform. Fynveur led the round with a €10 million investment, joined by existing shareholders and new private investors. A Bpifrance loan complements the equity financing, while Fynveur adviser Invus will join the company's board.
Founded in 2019 by aesthetic dentists Dr. Galip Gürel and Dr. Stefen Koubi, Lupin Dental is building a robotic system for minimally invasive tooth preparation before aesthetic veneers and other complex treatments. Its software designs the intended smile and generates a preparation plan; a workstation then executes that plan under the dentist's supervision, according to EU-Startups.
Clinical expertise becomes a repeatable workflow
The commercial proposition is not that automation replaces the dentist. It is that a carefully defined clinical technique can be encoded into a consistent, supervised workflow. Lupin Dental says the system is intended to make complex preparation procedures available to practitioners who have not spent decades developing the founders' manual expertise. If the approach works at scale, the product could help practices standardise a precision-sensitive part of aesthetic dentistry while keeping the clinician in control.
That promise already has a route to market in two jurisdictions. Lupin Dental announced UKCA certification in June 2026, allowing commercialisation in Great Britain, after obtaining regulatory clearance in India. The company also reported its first commercial installation at Pharande Dental Hospital in Pune in November 2025. In India, the technology is licensed to Dolphin Lifesciences, which manufactures and distributes it as the Dolphin Robotic Dental System.
Market access is the next operating test
The funding announcement says Lupin Dental plans to expand partnerships with academic and medical institutions, individual dentists and Dental Service Organisations. Those relationships can do more than distribute hardware: they can produce clinical evidence, training routines and reference sites that support adoption in a regulated market.
The company is explicit that the system is not approved for clinical use in the European Union or the United States. That makes regulatory progress and local delivery capacity central to the investment case. Lupin Dental has demonstrated a first installation and gained access to Great Britain, but the Series A still has to turn those milestones into repeatable deployments across markets with different approval, training and service requirements.
